HAI SOLUTIONS
FDA De Novo DEN250004
$89 / bed / month · Unlimited Caps
QIKcap™ Forecasted Financial Impact
Defensible ROI estimates built for VAC review. Adjust assumptions to match your facility's risk profile.
Your Facility Parameters
Hospital Beds Enrolleddrives your cost
20beds
5500
Baseline CABSI Rate
1.0per 1,000 CL-days
0.55.0
Attribution Assumption Set
Drag the sliders below to customize. Only connector-related CABSIs are attributed to QIKcap.
```Current Attribution
40% connector × 65% reduction
= total CABSI reduction attributed to QIKcap
= total CABSI reduction attributed to QIKcap
~30–50% of CABSIs are hub/connector-related · QIKcap active UV-C supports 60–70% reduction
26%
attributed
reduction
reduction
Connector-Related CABSI %literature: 30–50%
40%
10%60%
QIKcap Reduction of Those Eventsliterature: 50–70%
65%
30%85%
Your Annual Investment
$1,780
20 beds × $89 × 12 months
Unlimited cap usage included
→
Estimated Returns
$0
Direct cost + LOS recovery
Net savings as enrolled beds scale up ↓
0 beds▲ you are here400 beds
Monthly Subscription
$0
CABSIs Prevented
0.0
Effective Reduction
0%
Direct Cost Avoided
$0
$48,108 per CABSI (AHRQ)
Return on Investment
0%
Breakeven Point
0.00
CABSIs prevented covers full annual cost
♻️ Premium Cap Recycle Service
```
Add Premium Disposable Cap Recycle Service
Reduces medical waste, landfill burden & hospital carbon footprint
+$10/bed/mo
Built to Survive VAC Scrutiny
These estimates credit QIKcap only for CABSIs caused by contaminated IV connectors — roughly 30–50% of all CABSIs — not the full bundle effect. The standard tier delivers $1.10 returned per $1 spent at conservative assumptions (rate 0.5). Adding the Premium Recycle service reduces that return by $0.01 to $1.09 per $1 spent — a negligible tradeoff for a measurable reduction in medical waste and carbon footprint. Moderate and aggressive scenarios scale proportionally above both floors.
ASSUMPTIONS & REFERENCES
CABSI Attribution
[1] Safdar N, Kluger DM, Maki DG. "A review of risk factors for catheter-related bloodstream infection caused by percutaneously inserted, noncuffed central venous catheters." Medicine 2002;81(6):466–479. (30–50% of CABSIs are hub/connector-origin.)
[2] Mermel LA. "What is the predominant source of intravascular catheter infections?" Clin Infect Dis 2011;52(2):211–212.
Disinfection Cap Efficacy
[3] Ramirez C, et al. "Reduction of healthcare-associated infections using passive disinfection caps." Am J Infect Control 2010. (50–60% reduction in connector-related events.)
[4] Sweet MA, et al. "Impact of alcohol-impregnated port protectors and needleless neutral pressure connectors on central line-associated bloodstream infections." Infect Control Hosp Epidemiol 2012;33(6):645–648.
CABSI Cost & Length of Stay
[5] Agency for Healthcare Research and Quality (AHRQ). Saving Lives and Saving Money: Hospital-Acquired Conditions Update. 2019. ($48,108 attributable cost per CABSI.)
[6] Laguio-Vila M, et al. "Excess length of stay attributable to central line-associated bloodstream infections." Presented at IDSA Annual Meeting 2023. (13.4 excess hospital days per CABSI.)
[7] Length of stay cost estimated at $2,500/day (AHRQ national inpatient cost benchmarks).
Green / Recycle Program
[8] U.S. EPA. Waste Reduction Model (WARM). Version 15, 2019. (Plastics landfill vs. recycling CO₂e factors.)
[9] Practice Greenhealth. Sustainability Benchmark Report. 2022. (Medical-grade plastic disposal cost range $0.08–$0.18/unit; hospital carbon cost $45–$65/tonne CO₂e.)
[10] U.S. EPA GHG Equivalencies Calculator. 1 tonne CO₂ ≈ 12 trees grown for 10 years; ≈ 2,481 miles driven (404g CO₂/mile avg passenger vehicle); ≈ 550 kWh electricity consumed. QIKcap™ cap weight: 0.5g polypropylene; CO₂e factor: 0.0015 kg/cap (polypropylene manufacturing ~3 kg CO₂/kg resin, EPA AP-42).
Pricing
QIKcap™ standard subscription: $89/bed/month, unlimited caps • Premium Cap Recycle Service: $99/bed/month • FDA De Novo clearance granted December 30, 2025 (DEN250004) — first UV-C-based microbial reduction device cleared for luer-activated valves.
[1] Safdar N, Kluger DM, Maki DG. "A review of risk factors for catheter-related bloodstream infection caused by percutaneously inserted, noncuffed central venous catheters." Medicine 2002;81(6):466–479. (30–50% of CABSIs are hub/connector-origin.)
[2] Mermel LA. "What is the predominant source of intravascular catheter infections?" Clin Infect Dis 2011;52(2):211–212.
Disinfection Cap Efficacy
[3] Ramirez C, et al. "Reduction of healthcare-associated infections using passive disinfection caps." Am J Infect Control 2010. (50–60% reduction in connector-related events.)
[4] Sweet MA, et al. "Impact of alcohol-impregnated port protectors and needleless neutral pressure connectors on central line-associated bloodstream infections." Infect Control Hosp Epidemiol 2012;33(6):645–648.
CABSI Cost & Length of Stay
[5] Agency for Healthcare Research and Quality (AHRQ). Saving Lives and Saving Money: Hospital-Acquired Conditions Update. 2019. ($48,108 attributable cost per CABSI.)
[6] Laguio-Vila M, et al. "Excess length of stay attributable to central line-associated bloodstream infections." Presented at IDSA Annual Meeting 2023. (13.4 excess hospital days per CABSI.)
[7] Length of stay cost estimated at $2,500/day (AHRQ national inpatient cost benchmarks).
Green / Recycle Program
[8] U.S. EPA. Waste Reduction Model (WARM). Version 15, 2019. (Plastics landfill vs. recycling CO₂e factors.)
[9] Practice Greenhealth. Sustainability Benchmark Report. 2022. (Medical-grade plastic disposal cost range $0.08–$0.18/unit; hospital carbon cost $45–$65/tonne CO₂e.)
[10] U.S. EPA GHG Equivalencies Calculator. 1 tonne CO₂ ≈ 12 trees grown for 10 years; ≈ 2,481 miles driven (404g CO₂/mile avg passenger vehicle); ≈ 550 kWh electricity consumed. QIKcap™ cap weight: 0.5g polypropylene; CO₂e factor: 0.0015 kg/cap (polypropylene manufacturing ~3 kg CO₂/kg resin, EPA AP-42).
Pricing
QIKcap™ standard subscription: $89/bed/month, unlimited caps • Premium Cap Recycle Service: $99/bed/month • FDA De Novo clearance granted December 30, 2025 (DEN250004) — first UV-C-based microbial reduction device cleared for luer-activated valves.
Schedule a trial evaluation, request clinical materials, or connect with our team. We work directly with infection prevention, nursing leadership, and value analysis committees.